![Stefan W. Henning](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan W.
Henning has been Senior Director Research and Technology for Avontec GmbH since September 2005.
Prior to joining Avontec, he was Research Director of Xerion Pharmaceuticals AG.
Dr. Henning received a PhD in Biochemistry and Immunology from the Eberhard Karls Universität Tübingen.
| Sociétés | Poste | Fin |
|---|---|---|
Xerion Pharmaceuticals AG
 Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops antibodies and therapeutic targets | Directeur Technique/Scientifique/R&D | - |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Discovers and develops novel therapeutic treatments for inflammatory disease | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Discovers and develops novel therapeutic treatments for inflammatory disease | Health Technology |
Eberhard Karls Universität Tübingen
 Eberhard Karls Universität Tübingen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xerion Pharmaceuticals AG
Xerion Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Develops antibodies and therapeutic targets | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
